An Introduction to Prostate Cancer
The management of prostate cancer has evolved rapidly over the last decade. There are now several approved treatments in the castration-resistant treatment setting, delivering significant benefits like overall survival rate. The androgen receptor-targeting agents are also now proving effective in the hormone-sensitive setting.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Prostate Cancer Content
Improving outcomes in prostate cancer: What is the role of PARP-inhibitor combination therapy?
Watch Dr Neal Shore discuss the use of PARP inhibitors for patients with mCRPC and consider their potential as combination treatment with androgen deprivation therapy.
- Discuss the use of combination PARP-inhibitor targeted therapy in the management of prostate cancer
- Evaluate how to select/identify patients for potential combination PARPi and androgen receptor targeted therapy for prostate cancer
- Review ongoing clinical trials exploring combination PARPi and androgen-receptor targeted therapy for prostate cancer
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Immunotherapy in Advanced Prostate Cancer
European Oncology & Haematology. 2020;16(1):44–50 DOI: https://doi.org/10.17925/EOH.2020.16.1.44
Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune checkpoint inhibitors, has been successful in the treatment of a variety of advanced common solid tumours, […]
Treatment Sequencing of Abiraterone Acetate plus Prednisone and Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
European Oncology & Haematology. 2019;15(2):92–7
Prostate cancer is the most common cancer and the third leading cause of cancer-related death amongst men in Europe.1 Established treatment options for early-stage disease include surgery, radiation therapy and active surveillance,2 whereas patients presenting with advanced disease usually receive hormonal therapy using medical or surgical castration as the initial treatment.2,3 Unfortunately, most advanced prostate cancers acquire resistance […]
Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer
We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population. Questions 1. What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) […]
Axel Merseburger, ESMO 2019 – Advances in metastatic hormone-sensitive prostate cancer
Our Editor-in-Chief, Axel Merseberger (University Hospital Schleswig-Holstein), joined us at ESMO 2019 to discuss current limitations in the treatment of metastatic hormone-sensitive prostate cancer, use of antiandrogen agents, and what the future may hold. Questions 1. What are the limitations of the current standard of care for metastatic hormone-sensitive prostate cancer (mHSPC)? (0:05) 2. […]
Targeted Alpha Therapy – Optimising Survival in Advanced Prostate Cancer
European Oncology & Haematology. 2018;14(Suppl 3);3–10
Targeted alpha therapy (TAT) is the delivery of high-energy alpha particles to cancer cells and the tumour microenvironment to treat cancer. After a survival benefit was shown for radium-223 versus standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC), radium-223 became the first approved TAT.1–3 In the European Society for Medical Oncology (ESMO) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!